This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kauffman, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kauffman, C. A.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, January 2007, p. 115-132, Vol. 20, No. 1
0893-8512/07/$08.00+0     doi:10.1128/CMR.00027-06

Histoplasmosis: a Clinical and Laboratory Update

Carol A. Kauffman*

Infectious Diseases Division, Department of Internal Medicine, Ann Arbor Veterans Affairs Healthcare System, University of Michigan Medical School, Ann Arbor, Michigan

Infection with Histoplasma capsulatum occurs commonly in areas in the Midwestern United States and Central America, but symptomatic disease requiring medical care is manifest in very few patients. The extent of disease depends on the number of conidia inhaled and the function of the host's cellular immune system. Pulmonary infection is the primary manifestation of histoplasmosis, varying from mild pneumonitis to severe acute respiratory distress syndrome. In those with emphysema, a chronic progressive form of histoplasmosis can ensue. Dissemination of H. capsulatum within macrophages is common and becomes symptomatic primarily in patients with defects in cellular immunity. The spectrum of disseminated infection includes acute, severe, life-threatening sepsis and chronic, slowly progressive infection. Diagnostic accuracy has improved greatly with the use of an assay for Histoplasma antigen in the urine; serology remains useful for certain forms of histoplasmosis, and culture is the ultimate confirming diagnostic test. Classically, histoplasmosis has been treated with long courses of amphotericin B. Today, amphotericin B is rarely used except for severe infection and then only for a few weeks, followed by azole therapy. Itraconazole is the azole of choice following initial amphotericin B treatment and for primary treatment of mild to moderate histoplasmosis.

* Mailing address: Infectious Diseases Division, Ann Arbor Veterans Affairs Healthcare System, 2215 Fuller Road, Ann Arbor, MI 48105. Phone: (734) 761-7984. Fax: (734) 769-7039. E-mail: ckauff{at}umich.edu.

Clinical Microbiology Reviews, January 2007, p. 115-132, Vol. 20, No. 1
0893-8512/07/$08.00+0     doi:10.1128/CMR.00027-06




This article has been cited by other articles:

  • Frank, K. M., Hogarth, D. K., Miller, J. L., Mandal, S., Mease, P. J., Samulski, R. J., Weisgerber, G. A., Hart, J. (2009). Investigation of the Cause of Death in a Gene-Therapy Trial. NEJM 361: 161-169 [Abstract] [Full Text]  
  • Qualtieri, J., Stratton, C. W., Head, D. R., Tang, Y.-W. (2009). PCR Detection of Histoplasma capsulatum var. capsulatum in Whole Blood of a Renal Transplant Patient with Disseminated Histoplasmosis. Annals of Clinical & Laboratory Science 39: 409-412 [Abstract] [Full Text]  
  • Nguyen, V. Q., Sil, A. (2008). Temperature-induced switch to the pathogenic yeast form of Histoplasma capsulatum requires Ryp1, a conserved transcriptional regulator. Proc. Natl. Acad. Sci. USA 105: 4880-4885 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»